The Federal Trade Commission says Abbott Laboratories (ABT) can proceed with its proposed $25 billion acquisition of St. Jude Medical (STJ) . As a result of the green light, Abbott will sell two medical device units to Tokyo-based Terumo for $1.2 billion. The merger of Abbot and St. Jude was cleared by European antitrust regulators back in November, provided that U.S. regulators were on board with the transaction.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.